Impact of hypertension on global cardiovascular risk stratification: Analysis of a large cohort of outpatient population in Italy

Clinical Cardiology

Volumn 38, Issue 1, 2015, Pages 39-47

  Tocci, Giuliano ^a,b   Battistoni, Allegra ^a   D'Agostino, Michela ^a   Palano, Francesca ^a   Passerini, Jasmine ^a   Francia, Pietro ^a   Ferrucci, Andrea ^a   Volpe, Massimo ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OMEGA 3 FATTY ACID; TICLOPIDINE; TRIACYLGLYCEROL; CHOLESTEROL; GLUCOSE BLOOD LEVEL;

AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; COMORBIDITY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; FAMILY HISTORY; FEMALE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; HYPERTENSION; ITALY; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; OBESITY; OUTPATIENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHYSICAL ACTIVITY; PRESCRIPTION; RISK ASSESSMENT; SMOKING; SMOKING CESSATION; SMOKING HABIT; SYSTOLIC BLOOD PRESSURE; TRANSIENT ISCHEMIC ATTACK; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR DISEASE; WAIST CIRCUMFERENCE; ANALYSIS; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COMPLICATION; DYSLIPIDEMIAS; MIDDLE AGED; PREVALENCE; RISK FACTOR;

AGED; BLOOD GLUCOSE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL; COHORT STUDIES; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERTENSION; ITALY; MALE; MIDDLE AGED; OBESITY; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; SMOKING;

EID: 84922616879     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22351     Document Type: Article

References (28)

1. Staessen JA, Wang J, Bianchi G, et al. Essential hypertension. Lancet. 2003;361:1629-1641.
2. Turnbull F, Neal B, Ninomiya T, et al Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ. 2008;336:1121-1123.
3. Turnbull F, Neal B, Algert C, et al Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165:1410-1419.
4. Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-1535.
5. Bramlage P, Böhm M, Volpe M, et al. A global perspective on blood pressure treatment and control in a referred cohort of hypertensive patients. J Clin Hypertens (Greenwich). 2010;12:666-677.
6. Ignatius J. "RR 160/80" Scipione Riva-Rocci (1863-1937) [article in Finnish]. Duodecim. 1993;109:1493-1494.
7. Prugger C, Keil U, Wellmann J, et al EUROASPIRE III Study Group. Blood pressure control and knowledge of target blood pressure in coronary patients across Europe: results from the EUROASPIRE III survey. J Hypertens. 2011;29:1641-1648.
8. Chobanian AV. Shattuck Lecture. The hypertension paradox - more uncontrolled disease despite improved therapy [published correction appears in N Engl J Med. 2009;361:1516]. N Engl J Med. 2009;361:878-887.
9. Lee MS, Flammer AJ, Li J, et al. Time-trend analysis on the Framingham risk score and prevalence of cardiovascular risk factors in patients undergoing percutaneous coronary intervention without prior history of coronary vascular disease over the last 17 years: a study from the Mayo Clinic PCI registry. Clin Cardiol. 2014;37:408-416.
10. Volpe M. The changing role of hypertension societies: shifting gears in Italy. High Blood Press Cardiovasc Prev. 2012;19:1-2.
11. Wenger NK. Prevention of cardiovascular disease: highlights for the clinician of the 2013 American College of Cardiology/American Heart Association guidelines. Clin Cardiol. 2014;37:239-251.
12. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-2219.
13. Volpe M, Tocci G, Avogaro A, et al. Global cardiovascular risk assessment in different clinical settings: basal results of the EFFECTUS (Evaluation of Final Feasible Effect of Control Training and Ultra-Sensitisation) programme. High Blood Press Cardiovasc Prev. 2009;16:55-63.
14. Tocci G, Ferrucci A, Guida P, et al EFFECTUS Steering Committee. Impact of diabetes mellitus on the clinical management of global cardiovascular risk: analysis of the results of the Evaluation of Final Feasible Effect of Control Training and Ultra Sensitization (EFFECTUS) educational program. Clin Cardiol. 2011;34:560-566.
15. Tocci G, Ferrucci A, Guida P, et al EFFECTUS Steering Committee. Use of electronic support for implementing global cardiovascular risk management: analysis of the results of the EFFECTUS (Evaluation of Final Feasible Effect of Control Training and Ultra Sensitisation) educational programme. High Blood Press Cardiovasc Prev. 2010;17:37-47.
16. Tocci G, Ferrucci A, Guida P, et al. Global cardiovascular risk management in different Italian regions: an analysis of the Evaluation of Final Feasible Effect of Control Training and Ultra Sensitisation (EFFECTUS) educational program. Nutr Metab Cardiovasc Dis. 2012;22:635-642.
17. Chalmers J, MacMahon S, Mancia G, et al; Guidelines subcommittee of the World Health Organization. 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Clin Exp Hypertens. 1999;21:1009-1060.
18. Whitworth JA; World Health Organization International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21:1983-1992.
19. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
20. Grundy SM, Brewer HB Jr, Cleeman JI, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433-438.
21. Sesti G, Volpe M, Cosentino F, et al. Metabolic syndrome: diagnosis and clinical management - an official document of the Working Group of the Italian Society of Cardiovascular Prevention (SIPREC), Guest Editor: E. Agabiti Rosei, President of the Italian Society of Hypertension. High Blood Press Cardiovasc Prev. 2006;13:185-198.
22. Rydén L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;28:88-136.
23. Tocci G, Trimarco B, Mancia G, et al. Cardiovascular risk profile in 14 513 patients with essential hypertension followed by Italian specialist physicians. High Blood Press Cardiovasc Prev. 2004;11:165-173.
24. Volpe M, Notaro LA, Tocci G, et al. The Reassessment of Antihypertensive Chronic Therapy (REACT) Study: an Italian observational study on hypertension management in patients with established therapy. High Blood Press Cardiovasc Prev. 2004;11:175-185.
25. Mancia G, Ambrosioni E, Rosei EA, et al. Blood pressure control and risk of stroke in untreated and treated hypertensive patients screened from clinical practice: results of the ForLife study. J Hypertens. 2005;23:1575-1581.
26. Tocci G, Rosei EA, Ambrosioni E, et al. Blood pressure control in Italy: analysis of clinical data from 2005-2011 surveys on hypertension. J Hypertens. 2012;30:1065-1074.
27. Volpe M, Tocci G, Trimarco B, et al. Blood pressure control in Italy: results of recent surveys on hypertension. J Hypertens. 2007;25:1491-1498.
28. Giorda CB, Guida P, Avogaro A, et al EFFECTUS Steering Committee. Association of physicians' accuracy in recording with quality of care in cardiovascular medicine. Eur J Cardiovasc Prev Rehabil. 2009;16:722-728.